Skip to content
2000
Volume 25, Issue 14
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Background

Despite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common, with low overall survival rates. G protein–coupled receptor, class C, group 5, and member D (GPRC5D) has been expressed in several myeloma cell lines and has demonstrated encouraging outcomes results in studies as a potential target for immunotherapies.

Objective

We aimed to investigate the safety and efficacy of GPRC5D-targeted CAR T cell therapies in MM patients.

Methods

On August 24, 2023, the databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two‐step title/abstract and full-text screening process, the eligible studies were included.

Results

Following the screening of 107 articles, four studies of 130 multiple myeloma patients treated with GPRC5D-targeted CAR T-cell therapy were included. The meta-analyses showed an ORR of 87% (95% CI [81-93%]), with 74% (95% CI [65-73%]) for those with prior BCMA-targeted therapy and 88% (95% CI [78-99%]) for those without. PR was 25%, VGPR 33%, and CR/sCR 48%, with 65% achieving MRD-negativity. In terms of safety, hematologic AEs were common, with anemia reported in 86% of patients. Non-hematologic common AEs included CRS (83%, 5% grade ≥3) and hypocalcemia (63%, 10% grade ≥3). No significant publication bias was detected.

Conclusion

GPRC5D is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (R/R) MM and heavily pretreated patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206350342241224073809
2025-01-30
2025-10-26

  • From This Site

    /content/journals/acamc/10.2174/0118715206350342241224073809
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SiegelR.L. MillerK.D. JemalA. Cancer statistics, 2016.CA Cancer J. Clin.201666173010.3322/caac.2133226742998
     [Google Scholar]
  2. GereckeC. FuhrmannS. StriflerS. Schmidt-HieberM. EinseleH. KnopS. The diagnosis and treatment of multiple myeloma.Dtsch. Arztebl. Int.201611327-2847047610.3238/arztebl.2016.047027476706
     [Google Scholar]
  3. RajkumarS.V. KumarS. Eds.; Multiple myeloma: Diagnosis and treatment. Mayo Clinic Proceedings.Elsevier2016
     [Google Scholar]
  4. MinakataD. FujiwaraS. YokoyamaD. NoguchiA. AoeS. OyamaT. KoyamaS. MurahashiR. NakashimaH. HyodoK. IkedaT. KawaguchiS. TodaY. ItoS. NagayamaT. MashimaK. UminoK. MoritaK. AshizawaM. YamamotoC. HatanoK. SatoK. OhmineK. KandaY. Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies.Br. J. Haematol.2023200669470310.1111/bjh.1865436661264
     [Google Scholar]
  5. CowanA.J. GreenD.J. KwokM. LeeS. CoffeyD.G. HolmbergL.A. TuazonS. GopalA.K. LibbyE.N. Diagnosis and management of multiple myeloma: A review.JAMA2022327546447710.1001/jama.2022.000335103762
     [Google Scholar]
  6. AbdallahN. RajkumarS.V. GreippP. KapoorP. GertzM.A. DispenzieriA. BaughnL.B. LacyM.Q. HaymanS.R. BuadiF.K. DingliD. GoR.S. HwaY.L. FonderA. HobbsM. LinY. LeungN. KourelisT. WarsameR. SiddiquiM. LustJ. KyleR.A. BergsagelL. KetterlingR. KumarS.K. Cytogenetic abnormalities in multiple myeloma: Association with disease characteristics and treatment response.Blood Cancer J.20201088210.1038/s41408‑020‑00348‑532782240
     [Google Scholar]
  7. MunshiN.C. AndersonL.D.Jr ShahN. MadduriD. BerdejaJ. LonialS. RajeN. LinY. SiegelD. OriolA. MoreauP. Yakoub-AghaI. DelforgeM. CavoM. EinseleH. GoldschmidtH. WeiselK. RambaldiA. ReeceD. PetroccaF. MassaroM. ConnarnJ.N. KaiserS. PatelP. HuangL. CampbellT.B. HegeK. San-MiguelJ. Idecabtagene vicleucel in relapsed and refractory multiple myeloma.N. Engl. J. Med.2021384870571610.1056/NEJMoa202485033626253
     [Google Scholar]
  8. LonialS. DimopoulosM. PalumboA. WhiteD. GrosickiS. SpickaI. Walter-CroneckA. MoreauP. MateosM.V. MagenH. BelchA. ReeceD. BeksacM. SpencerA. OakerveeH. OrlowskiR.Z. TaniwakiM. RölligC. EinseleH. WuK.L. SinghalA. San-MiguelJ. MatsumotoM. KatzJ. BleickardtE. PoulartV. AndersonK.C. RichardsonP. ELOQUENT-2 Investigators Elotuzumab therapy for relapsed or refractory multiple myeloma.N. Engl. J. Med.2015373762163110.1056/NEJMoa150565426035255
     [Google Scholar]
  9. AbramsonH.N. The multiple myeloma drug pipeline—2018: A review of small molecules and their therapeutic targets.Clin. Lymphoma Myeloma Leuk.201818961162710.1016/j.clml.2018.06.01530001985
     [Google Scholar]
  10. MagarottoV. SalviniM. BonelloF. BringhenS. PalumboA. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Leuk. Lymphoma201657353755610.3109/10428194.2015.110224526445358
     [Google Scholar]
  11. ZhangM. WeiG. ZhouL. ZhouJ. ChenS. ZhangW. WangD. LuoX. CuiJ. HuangS. FuS. ZhouX. TangY. DingX. KuangJ. HeX.P. HuY. HuangH. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial.Lancet Haematol.2023102e107e11610.1016/S2352‑3026(22)00372‑636725117
     [Google Scholar]
  12. RoexG. FeysT. BeguinY. KerreT. PoiréX. LewalleP. VandenbergheP. BronD. AnguilleS. Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: An update of the pivotal clinical trial data.Pharmaceutics202012219410.3390/pharmaceutics1202019432102267
     [Google Scholar]
  13. StoiberS. CadilhaB.L. BenmebarekM.R. LeschS. EndresS. KoboldS. Limitations in the design of chimeric antigen receptors for cancer therapy.Cells20198547210.3390/cells805047231108883
     [Google Scholar]
  14. MikkilineniL. KochenderferJ.N. Chimeric antigen receptor T-cell therapies for multiple myeloma.Blood2017130242594260210.1182/blood‑2017‑06‑79386928928126
     [Google Scholar]
  15. XuD. JinG. ChaiD. ZhouX. GuW. ChongY. SongJ. ZhengJ. The development of CAR design for tumor CAR-T cell therapy.Oncotarget2018917139911400410.18632/oncotarget.2417929568411
     [Google Scholar]
  16. MikkilineniL. KochenderferJ.N. CAR T cell therapies for patients with multiple myeloma.Nat. Rev. Clin. Oncol.2021182718410.1038/s41571‑020‑0427‑632978608
     [Google Scholar]
  17. RajeN. BerdejaJ. LinY. SiegelD. JagannathS. MadduriD. LiedtkeM. RosenblattJ. MausM.V. TurkaA. LamL.P. MorganR.A. FriedmanK. MassaroM. WangJ. RussottiG. YangZ. CampbellT. HegeK. PetroccaF. QuigleyM.T. MunshiN. KochenderferJ.N. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.N. Engl. J. Med.2019380181726173710.1056/NEJMoa181722631042825
     [Google Scholar]
  18. FirestoneR.S. MailankodyS. Current use of CAR T cells to treat multiple myeloma.Hematology20232023134034710.1182/hematology.202300043438066841
     [Google Scholar]
  19. Reguera-OrtegaJ.L. García-GuerreroE. Pérez-SimónJ.A. Current status of CAR-T cell therapy in multiple myeloma.Hemato20212466067110.3390/hemato2040043
     [Google Scholar]
  20. SadelainM. BrentjensR. RivièreI. The basic principles of chimeric antigen receptor design.Cancer Discov.20133438839810.1158/2159‑8290.CD‑12‑054823550147
     [Google Scholar]
  21. KochenderferJ.N. WilsonW.H. JanikJ.E. DudleyM.E. Stetler-StevensonM. FeldmanS.A. MaricI. RaffeldM. NathanD.A.N. LanierB.J. MorganR.A. RosenbergS.A. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood2010116204099410210.1182/blood‑2010‑04‑28193120668228
     [Google Scholar]
  22. MorèS. PetrucciM. CorvattaL. FazioF. OffidaniM. OlivieriA. Monoclonal antibodies: Leading actors in the relapsed/refractory multiple myeloma treatment.Pharmaceuticals2020131242610.3390/ph1312042633260960
     [Google Scholar]
  23. BahlisN.J. DimopoulosM.A. WhiteD.J. BenboubkerL. CookG. LeibaM. HoP.J. KimK. TakezakoN. MoreauP. KaufmanJ.L. KrevvataM. ChiuC. QinX. OkonkwoL. TrivediS. UkropecJ. QiM. San-MiguelJ. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study.Leukemia20203471875188410.1038/s41375‑020‑0711‑632001798
     [Google Scholar]
  24. SchubertM.L. SchmittM. WangL. RamosC.A. JordanK. Müller-TidowC. DregerP. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.Ann. Oncol.2021321344810.1016/j.annonc.2020.10.47833098993
     [Google Scholar]
  25. ChadwickD. The price of hope: Weighing the cost of CAR-T cell therapy in treating blood cancers.Curetoday Hematol.20202020
     [Google Scholar]
  26. RendoM.J. JosephJ.J. PhanL.M. DeStefanoC.B. CAR T-cell therapy for patients with multiple myeloma: Current evidence and challenges.Blood Lymphat. Cancer20221211913610.2147/BLCTT.S32701636060553
     [Google Scholar]
  27. ChariA. Martinez-LopezJ. MateosM.V. BladéJ. BenboubkerL. OriolA. ArnulfB. Rodriguez-OteroP. PineiroL. JakubowiakA. de BoerC. WangJ. ClemensP.L. UkropecJ. SchecterJ. LonialS. MoreauP. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.Blood2019134542143110.1182/blood.201900072231113777
     [Google Scholar]
  28. AyedA.O. ChangL.J. MorebJ.S. Immunotherapy for multiple myeloma: Current status and future directions.Crit. Rev. Oncol. Hematol.201596339941210.1016/j.critrevonc.2015.06.00626153389
     [Google Scholar]
  29. BadrosA. HyjekE. MaN. LesokhinA. DoganA. RapoportA.P. KocogluM. LedererE. PhilipS. MillironT. DellC. GoloubevaO. SinghZ. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.Blood2017130101189119710.1182/blood‑2017‑03‑77512228461396
     [Google Scholar]
  30. JungS.H. LeeH.J. LeeY.K. YangD.H. KimH.J. RheeJ.H. EmmrichF. LeeJ.J. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.Oncotarget2017825415384154810.18632/oncotarget.1458228088784
     [Google Scholar]
  31. ChoS.F. AndersonK.C. TaiY.T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy.Front. Immunol.20189182110.3389/fimmu.2018.0182130147690
     [Google Scholar]
  32. TaiY.T. AndersonK.C. Targeting B-cell maturation antigen in multiple myeloma.Immunotherapy20157111187119910.2217/imt.15.7726370838
     [Google Scholar]
  33. BuD.X. SinghR. ChoiE.E. RuellaM. Nunez-CruzS. MansfieldK.G. BennettP. BartonN. WuQ. ZhangJ. WangY. WeiL. CoganS. EzellT. JoshiS. LatimerK.J. GrandaB. TschantzW.R. YoungR.M. HuetH.A. RichardsonC.J. MiloneM.C. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.Oncotarget2018940257642578010.18632/oncotarget.2535929899820
     [Google Scholar]
  34. OdenF. MarinoS.F. BrandJ. ScheuS. KriegelC. OlalD. TakvorianA. WestermannJ. YilmazB. HinzM. DaumkeO. HöpkenU.E. MüllerG. LippM. Potent anti‐tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.Mol. Oncol.2015971348135810.1016/j.molonc.2015.03.01025953704
     [Google Scholar]
  35. DemelI. BagoJ.R. HajekR. JelinekT. Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: Update 2021.Br. J. Haematol.2021193470572210.1111/bjh.1723533216972
     [Google Scholar]
  36. SmithE.L. HarringtonK. StaehrM. MasakayanR. JonesJ. LongT.J. NgK.Y. GhoddusiM. PurdonT.J. WangX. DoT. PhamM.T. BrownJ.M. De LarreaC.F. OlsonE. PegueroE. WangP. LiuH. XuY. Garrett-ThomsonS.C. AlmoS.C. WendelH.G. RiviereI. LiuC. SatherB. BrentjensR.J. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.Sci. Transl. Med.201911485eaau774610.1126/scitranslmed.aau774630918115
     [Google Scholar]
  37. AtamaniukJ. GleissA. PorpaczyE. KainzB. GruntT.W. RadererM. HilgarthB. DrachJ. LudwigH. GisslingerH. JaegerU. GaigerA. Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.Eur. J. Clin. Invest.201242995396010.1111/j.1365‑2362.2012.02679.x22591013
     [Google Scholar]
  38. GagelmannN. BrudnoJ. GPRC5D-targeting chimeric antigen receptors: A new treatment for multiple myeloma?Lancet Haematol.2023102e82e8310.1016/S2352‑3026(22)00385‑436725123
     [Google Scholar]
  39. SmithE.L. HarringtonK. StaehrM. MasakayanR. JonesJ. LongT. GhoddusiM. PurdonT.J. DoT. WangX. PhamM. BrownJ.M. PegueroE. Fernández De LarreaC. WangP. LiuH. XuY. GarrettS. AlmoS. RiviereI. LiuC. SatherB.D. BrentjensR.J. CAR T cell therapy targeting G protein-coupled receptor class C group 5 member D (GPRC5D), a novel target for the immunotherapy of multiple myeloma.Blood2018132Suppl. 158910.1182/blood‑2018‑99‑110471
     [Google Scholar]
  40. LeeH. AhnS. MaityR. LeblayN. ZicchedduB. TrugerM. ChojnackaM. CirrincioneA. DuranteM. TilmontR. BarakatE. PoorebrahimM. SinhaS. McIntyreJ. M Y ChanA. WilsonH. KymanS. KrishnanA. LandgrenO. WalterW. MeggendorferM. HaferlachC. HaferlachT. EinseleH. KortümM.K. KnopS. AlbergeJ.B. RosenwaldA. KeatsJ.J. RascheL. MauraF. NeriP. BahlisN.J. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.Nat. Med.20232992295230610.1038/s41591‑023‑02491‑537653344
     [Google Scholar]
  41. Fernandez de LarreaC. StaehrM. LopezA. ChenY. PurdonT.J. NgK.Y. WendelH. BrentjensR.J. SmithE.L. Optimal dual-targeted CAR construct simultaneously targeting Bcma and GPRC5D prevents Bcma-escape driven relapse in multiple myeloma.Blood2019134Suppl. 113610.1182/blood‑2019‑126145
     [Google Scholar]
  42. PageM.J. McKenzieJ.E. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. Mayo-WilsonE. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. MoherD. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.Int. J. Surg.20218810590610.1016/j.ijsu.2021.10590633789826
     [Google Scholar]
  43. SlimK. NiniE. ForestierD. KwiatkowskiF. PanisY. ChipponiJ. Methodological index for non‐randomized studies ( MINORS ): Development and validation of a new instrument.ANZ J. Surg.200373971271610.1046/j.1445‑2197.2003.02748.x12956787
     [Google Scholar]
  44. HigginsJ. Cochrane handbook for systematic reviews of interventions.2011Available from: www.cochrane-handbookorg
  45. KumarS.K. CallanderN.S. AdekolaK. AndersonL.D.Jr BaljevicM. BazR. CampagnaroE. CastilloJ.J. CostelloC. D’AngeloC. DevarakondaS. ElsedawyN. GarfallA. GodbyK. HillengassJ. HolmbergL. HtutM. HuffC.A. HultcrantzM. KangY. LarsonS. LeeH.C. LiedtkeM. MartinT. OmelJ. RobinsonT. RosenbergA. SborovD. SchroederM.A. SherbenouD. SuvannasankhaA. ValentJ. Varshavsky-YanovskyA.N. KumarR. SnedekerJ. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology.J. Natl. Compr. Canc. Netw.202321121281130110.6004/jnccn.2023.006138081133
     [Google Scholar]
  46. PennisiM. JainT. SantomassoB.D. MeadE. WudhikarnK. SilverbergM.L. BatleviY. ShouvalR. DevlinS.M. BatleviC. BrentjensR.J. DahiP.B. DiamonteC. GiraltS. HaltonE.F. MaloyM. PalombaM.L. Sanchez-EscamillaM. SauterC.S. ScordoM. ShahG. ParkJ.H. PeralesM.A. Comparing CAR T-cell toxicity grading systems: Application of the ASTCT grading system and implications for management.Blood Adv.20204467668610.1182/bloodadvances.201900095232084260
     [Google Scholar]
  47. LeeD.W. SantomassoB.D. LockeF.L. GhobadiA. TurtleC.J. BrudnoJ.N. MausM.V. ParkJ.H. MeadE. PavleticS. GoW.Y. EldjerouL. GardnerR.A. FreyN. CurranK.J. PeggsK. PasquiniM. DiPersioJ.F. van den BrinkM.R.M. KomanduriK.V. GruppS.A. NeelapuS.S. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol. Blood Marrow Transplant.201925462563810.1016/j.bbmt.2018.12.75830592986
     [Google Scholar]
  48. BrudnoJ.N. KochenderferJ.N. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.Blood Rev.201934455510.1016/j.blre.2018.11.00230528964
     [Google Scholar]
  49. KochenderferJ.N. SomervilleR.P.T. LuT. ShiV. BotA. RossiJ. XueA. GoffS.L. YangJ.C. SherryR.M. KlebanoffC.A. KammulaU.S. ShermanM. PerezA. YuanC.M. FeldmanT. FriedbergJ.W. RoschewskiM.J. FeldmanS.A. McIntyreL. ToomeyM.A. RosenbergS.A. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels.J. Clin. Oncol.201735161803181310.1200/JCO.2016.71.302428291388
     [Google Scholar]
  50. MailankodyS. DevlinS.M. LandaJ. NathK. DiamonteC. CarstensE.J. RussoD. AuclairR. FitzgeraldL. CadzinB. WangX. SikderD. SenechalB. BermudezV.P. PurdonT.J. HosszuK. McAvoyD.P. FarzanaT. MeadE. WilcoxJ.A. SantomassoB.D. ShahG.L. ShahU.A. KordeN. LesokhinA. TanC.R. HultcrantzM. HassounH. RoshalM. SenF. DoganA. LandgrenO. GiraltS.A. ParkJ.H. UsmaniS.Z. RivièreI. BrentjensR.J. SmithE.L. GPRC5D-targeted CAR T cells for myeloma.N. Engl. J. Med.2022387131196120610.1056/NEJMoa220990036170501
     [Google Scholar]
  51. XiaJ. LiH. YanZ. ZhouD. WangY. QiY. CaoJ. LiD. ChengH. SangW. ZhuF. SunH. ChenW. QiK. YanD. QiuT. QiaoJ. YaoR. LiuY. WangX. ZhangY. PengS. HuangC.H. ZhengJ. LiZ. ChangA.H. XuK. Anti–G protein–coupled receptor, Class C Group 5 Member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase Ⅱ trial.J. Clin. Oncol.202341142583259310.1200/JCO.22.0182436881785
     [Google Scholar]
  52. BalS. KocogluM.H. NadeemO. HtutM. GregoryT. AndersonL.D.Jr CostaL.J. BuchholzT.J. ZiyadS. LiM. ChenY. KaedingA.J. BurgessM.R. HegeK. BerdejaJ. Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): First results from a phase 1, multicenter, open-label study.Blood2022140Suppl. 188388510.1182/blood‑2022‑162395
     [Google Scholar]
  53. BalS. BerdejaJ. HtutM. KocogluM. GregoryT. AndersonL.D. RossiA. EganD. CostaL. KellyL. ZiyadS. HuH. ChenY. KaedingA.J. BurgessM. HegeK. NadeemO. S193: BMS-986393 (CC-95266), A G protein–coupled receptor Class C Group 5 Member D (GPRC5D)–targeted car t-cell therapy for relapsed/refractory multiple myeloma (RRMM): Results from a phase 1 study.HemaSphere20237S3e986328710.1097/01.HS9.0000967684.98632.87
     [Google Scholar]
  54. WangD. WangJ. HuG. WangW. XiaoY. CaiH. JiangL. MengL. YangY. ZhouX. HongZ. YaoZ. XiaoM. ChenL. MaoX. ZhuL. WangJ. QiuL. LiC. ZhouJ. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.Blood2021137212890290110.1182/blood.202000893633512480
     [Google Scholar]
  55. KochenderferJ.N. DudleyM.E. FeldmanS.A. WilsonW.H. SpanerD.E. MaricI. Stetler-StevensonM. PhanG.Q. HughesM.S. SherryR.M. YangJ.C. KammulaU.S. DevillierL. CarpenterR. NathanD.A.N. MorganR.A. LaurencotC. RosenbergS.A. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells.Blood2012119122709272010.1182/blood‑2011‑10‑38438822160384
     [Google Scholar]
  56. KochenderferJ.N. DudleyM.E. KassimS.H. SomervilleR.P.T. CarpenterR.O. Stetler-StevensonM. YangJ.C. PhanG.Q. HughesM.S. SherryR.M. RaffeldM. FeldmanS. LuL. LiY.F. NgoL.T. GoyA. FeldmanT. SpanerD.E. WangM.L. ChenC.C. KranickS.M. NathA. NathanD.A.N. MortonK.E. ToomeyM.A. RosenbergS.A. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.J. Clin. Oncol.201533654054910.1200/JCO.2014.56.202525154820
     [Google Scholar]
  57. SantomassoB.D. ParkJ.H. SalloumD. RiviereI. FlynnJ. MeadE. HaltonE. WangX. SenechalB. PurdonT. CrossJ.R. LiuH. VachhaB. ChenX. DeAngelisL.M. LiD. BernalY. GonenM. WendelH.G. SadelainM. BrentjensR.J. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.Cancer Discov.20188895897110.1158/2159‑8290.CD‑17‑131929880584
     [Google Scholar]
  58. NeelapuS.S. TummalaS. KebriaeiP. WierdaW. GutierrezC. LockeF.L. KomanduriK.V. LinY. JainN. DaverN. WestinJ. GulbisA.M. LoghinM.E. de GrootJ.F. AdkinsS. DavisS.E. RezvaniK. HwuP. ShpallE.J. Chimeric antigen receptor T-cell therapy — Assessment and management of toxicities.Nat. Rev. Clin. Oncol.2018151476210.1038/nrclinonc.2017.14828925994
     [Google Scholar]
  59. GustJ. HayK.A. HanafiL.A. LiD. MyersonD. Gonzalez-CuyarL.F. YeungC. LilesW.C. WurfelM. LopezJ.A. ChenJ. ChungD. Harju-BakerS. ÖzpolatT. FinkK.R. RiddellS.R. MaloneyD.G. TurtleC.J. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.Cancer Discov.20177121404141910.1158/2159‑8290.CD‑17‑069829025771
     [Google Scholar]
  60. RoexG. TimmersM. WoutersK. Campillo-DavoD. FlumensD. SchroyensW. ChuY. BernemanZ.N. LionE. LuoF. AnguilleS. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.J. Hematol. Oncol.202013116410.1186/s13045‑020‑01001‑133272302
     [Google Scholar]
  61. HuD. ChenL. YanD. DongW. ChenM. NiuS. WangS. ZhangJ. NieX. FangY. Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: A comprehensive review and meta-analysis of prospective clinical trials.Front. Pharmacol.202314114913810.3389/fphar.2023.114913837408760
     [Google Scholar]
  62. KroschinskyF. StölzelF. von BoninS. BeutelG. KochanekM. KiehlM. SchellongowskiP. Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management.Crit. Care20172118910.1186/s13054‑017‑1678‑128407743
     [Google Scholar]
  63. McCulloughK.B. HobbsM.A. AbeykoonJ.P. KapoorP. Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies.Curr. Hematol. Malig. Rep.201813211412410.1007/s11899‑018‑0443‑029450683
     [Google Scholar]
  64. KumarS. PaivaB. AndersonK.C. DurieB. LandgrenO. MoreauP. MunshiN. LonialS. BladéJ. MateosM.V. DimopoulosM. KastritisE. BoccadoroM. OrlowskiR. GoldschmidtH. SpencerA. HouJ. ChngW.J. UsmaniS.Z. ZamagniE. ShimizuK. JagannathS. JohnsenH.E. TerposE. ReimanA. KyleR.A. SonneveldP. RichardsonP.G. McCarthyP. LudwigH. ChenW. CavoM. HarousseauJ.L. LentzschS. HillengassJ. PalumboA. OrfaoA. RajkumarS.V. MiguelJ.S. Avet-LoiseauH. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol.2016178e328e34610.1016/S1470‑2045(16)30206‑627511158
     [Google Scholar]
  65. BrudnoJ.N. MaricI. HartmanS.D. RoseJ.J. WangM. LamN. Stetler-StevensonM. SalemD. YuanC. PavleticS. KanakryJ.A. AliS.A. MikkilineniL. FeldmanS.A. StroncekD.F. HansenB.G. LawrenceJ. PatelR. HakimF. GressR.E. KochenderferJ.N. T cells genetically modified to express an anti–b-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma.J. Clin. Oncol.201836222267228010.1200/JCO.2018.77.808429812997
     [Google Scholar]
  66. LaurentS.A. HoffmannF.S. KuhnP.H. ChengQ. ChuY. Schmidt-SupprianM. HauckS.M. SchuhE. KrumbholzM. RübsamenH. WanngrenJ. KhademiM. OlssonT. AlexanderT. HiepeF. PfisterH.W. WeberF. JenneD. WekerleH. HohlfeldR. LichtenthalerS.F. MeinlE. γ-secretase directly sheds the survival receptor BCMA from plasma cells.Nat. Commun.201561733310.1038/ncomms833326065893
     [Google Scholar]
  67. van DongenJ.J.M. LhermitteL. BöttcherS. AlmeidaJ. van der VeldenV.H.J. Flores-MonteroJ. RawstronA. AsnafiV. LécrevisseQ. LucioP. MejstrikovaE. SzczepańskiT. KalinaT. de TuteR. BrüggemannM. SedekL. CullenM. LangerakA.W. MendonçaA. MacintyreE. Martin-AyusoM. HrusakO. VidrialesM.B. OrfaoA. EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.Leukemia20122691908197510.1038/leu.2012.12022552007
     [Google Scholar]
  68. MiX. PensonA. Abdel-WahabO. MailankodyS. Genetic basis of relapse after GPRC5D-targeted CAR T cells.N. Engl. J. Med.2023389151435143710.1056/NEJMc230854437819961
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206350342241224073809
Loading
A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 1017 (2025); https://doi.org/10.2174/0118715206350342241224073809
/content/journals/acamc/10.2174/0118715206350342241224073809
/content/journals/acamc/10.2174/0118715206350342241224073809
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): CAR T Cell; chimeric antigen receptor; GPRC5D; hematologic AEs; immunotherapy; Multiple myeloma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test